Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Aitziber Buqué, Norma Bloy, Fernando Aranda, Francesca Castoldi, Alexander Eggermont, Isabelle Cremer, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Aurélien Marabelle, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2015) Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology 4:4.
Read now
Read now
Lorenzo Galluzzi, Guido Kroemer & Alexander Eggermont. (2014) Novel immune checkpoint blocker approved for the treatment of advanced melanoma. OncoImmunology 3:11.
Read now
Read now
Erika Vacchelli, Fernando Aranda, Alexander Eggermont, Catherine Sautès-Fridman, Eric Tartour, Eugene P Kennedy, Michael Platten, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial watch: IDO inhibitors in cancer therapy. OncoImmunology 3:10.
Read now
Read now
Articles from other publishers (48)
Sara Ebrahimi, Adrina Habibzadeh, Soroush Khojasteh-Kaffash, Parya Valizadeh, Noosha Samieefar & Nima Rezaei. (2023) Immune Checkpoint Inhibitors Therapy as the Game-Changing Approach for Pediatric Lymphoma: A Brief Landscape. Critical Reviews in Oncology/Hematology, pages 104225.
Crossref
Crossref
Seyed Hossein Kiaie, Hossein Salehi-Shadkami, Mohammad Javad Sanaei, Marzieh Azizi, Mahdieh Shokrollahi Barough, Mohammad Sadegh Nasr & Mohammad Sheibani. (2023) Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy. Journal of Nanobiotechnology 21:1.
Crossref
Crossref
Wenshuai Li, Xuanxuan Pan, Lirong Chen, Haoshu Cui, Shaocong Mo, Yida Pan, Yuru Shen, Menglin Shi, Jianlin Wu, Feifei Luo, Jie Liu & Na Li. (2023) Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy. Frontiers in Immunology 14.
Crossref
Crossref
Lavinia Patricia Mocan, Rares Craciun, Cristiana Grapa, Carmen Stanca Melincovici, Ioana Rusu, Nadim Al Hajjar, Zeno Sparchez, Daniel Leucuta, Maria Ilies, Mihaela Sparchez, Tudor Mocan & Carmen Mihaela Mihu. (2022) PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma. Cancer Immunology, Immunotherapy 72:4, pages 1003-1014.
Crossref
Crossref
Yu-Shu Liu, Bor-Ren Huang, Ching-Ju Lin, Ching-Kai Shen, Sheng-Wei Lai, Chao-Wei Chen, Hui-Jung Lin, Chia-Huei Lin, Yun-Chen Hsieh & Dah-Yuu Lu. (2021) Paliperidone Inhibits Glioblastoma Growth in Mouse Brain Tumor Model and Reduces PD-L1 Expression. Cancers 13:17, pages 4357.
Crossref
Crossref
Weigang Xiu & Jingjing Luo. (2021) CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling. BMC Immunology 22:1.
Crossref
Crossref
Hyein Ahn, Hyun Ju Lee, Ji-Hye Lee, Hyun Deuk Cho, Mee-Hye Oh, Ji Woong Son & Si-Hyong Jang. (2020) Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer. Pathology - Research and Practice 216:11, pages 153188.
Crossref
Crossref
Zahra Payandeh, Saeed Khalili, Mohammad Hossein Somi, Maysam Mard‐Soltani, Amir Baghbanzadeh, Khalil Hajiasgharzadeh, Nasser Samadi & Behzad Baradaran. (2020) PD‐1/PD‐L1‐dependent immune response in colorectal cancer. Journal of Cellular Physiology 235:7-8, pages 5461-5475.
Crossref
Crossref
Feng Wang, Tao Yu, Chengbin Ma, Hongmou Yuan, Haifei Zhang & Zhiyu Zhang. (2020) Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients. Frontiers in Oncology 10.
Crossref
Crossref
Jeong Uk Choi, Ruby Maharjan, Rudra Pangeni, Saurav Kumar Jha, Na Kyeong Lee, Seho Kweon, Ha Kyeong Lee, Kwan-Young Chang, Young Kweon Choi, Jin Woo Park & Youngro Byun. (2020) Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion. Journal of Controlled Release 322, pages 13-30.
Crossref
Crossref
Martine Bocchini, Fabio Nicolini, Stefano Severi, Alberto Bongiovanni, Toni Ibrahim, Giorgia Simonetti, Ilaria Grassi & Massimiliano Mazza. (2020) Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review. Frontiers in Oncology 10.
Crossref
Crossref
Shima Bastaki, Mahzad Irandoust, Armin Ahmadi, Mohammad Hojjat-Farsangi, Patrick Ambrose, Shahin Hallaj, Mahdi Edalati, Ghasem Ghalamfarsa, Gholamreza Azizi, Mehdi Yousefi, Hengameh Chalajour & Farhad Jadidi-Niaragh. (2020) PD-L1/PD-1 axis as a potent therapeutic target in breast cancer. Life Sciences 247, pages 117437.
Crossref
Crossref
Wei Li, Meixiao Zhan, Ying-yao Quan, Hao Wang, Sheng-ni Hua, Yong Li, Jianjun Zhang, Ligong Lu & Min Cui. (2020) Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy. International Immunopharmacology 81, pages 106227.
Crossref
Crossref
Xinyu Liu, Yiwen Zhang, Huaichuan Duan, Qing Luo, Wei Liu, Li Liang, Hua Wan, Shan Chang, Jianping Hu & Hubing Shi. (2020) Inhibition Mechanism of Indoleamine 2, 3-Dioxygenase 1 (IDO1) by Amidoxime Derivatives and Its Revelation in Drug Design: Comparative Molecular Dynamics Simulations. Frontiers in Molecular Biosciences 6.
Crossref
Crossref
Anne Monette, Derek Bergeron, Amira Ben Amor, Liliane Meunier, Christine Caron, Anne-Marie Mes-Masson, Nidhameddine Kchir, Kamel Hamzaoui, Igor Jurisica & Réjean Lapointe. (2019) Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Federica Miglietta, Gaia Griguolo, Valentina Guarneri & Maria Vittoria Dieci. (2019) Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value. The Oncologist 24:11, pages e1055-e1069.
Crossref
Crossref
Giuseppe Schepisi, Nicole Brighi, Maria Concetta Cursano, Giorgia Gurioli, Giorgia Ravaglia, Amelia Altavilla, Salvatore Luca Burgio, Sara Testoni, Cecilia Menna, Alberto Farolfi, Chiara Casadei, Giuseppe Tonini, Daniele Santini & Ugo De Giorgi. (2019) Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. Journal of Oncology 2019, pages 1-11.
Crossref
Crossref
Yanheng Wu, Wenyi Gu, Jiang Li, Chen Chen & Zhi Ping Xu. (2019) Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes. Nanomedicine 14:8, pages 955-967.
Crossref
Crossref
Shichao Li, Li Chen & Jun Jiang. (2019) Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer. Medicine 98:16, pages e15201.
Crossref
Crossref
Elisabeth Specht Stovgaard, Anne Dyhl-Polk, Anne Roslind, Eva Balslev & Dorte Nielsen. (2019) PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review. Breast Cancer Research and Treatment 174:3, pages 571-584.
Crossref
Crossref
Tiffany Seto, Danny Sam & Minggui Pan. (2019) Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer. Medical Sciences 7:2, pages 14.
Crossref
Crossref
Pelagia G. Tsoutsou, Khalil Zaman, Silvia Martin Lluesma, Laurene Cagnon, Lana Kandalaft & Marie-Catherine Vozenin. (2018) Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. Frontiers in Oncology 8.
Crossref
Crossref
Sunyoung Park, Soyun Cho, Minji Kim, Ji Ung Park, Eui Cheol Jeong, Euno Choi, Jeong Hwan Park, Cheol Lee & Mee Soo Chang. (2018) Dermatofibrosarcoma protuberans: A retrospective study of clinicopathologic features and related Akt/mTOR, STAT3, ERK, cyclin D1, and PD-L1 expression. Journal of the American Academy of Dermatology 79:5, pages 843-852.
Crossref
Crossref
Nyanbol Kuol, Lily Stojanovska, Kulmira Nurgali & Vasso Apostolopoulos. (2018) PD-1/PD-L1 in disease. Immunotherapy 10:2, pages 149-160.
Crossref
Crossref
Nobumoto Tomioka, Manabu Azuma, Mayuko Ikarashi, Mitsugu Yamamoto, Masako Sato, Ken-ichi Watanabe, Katsushige Yamashiro & Masato Takahashi. (2017) The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer 25:1, pages 34-42.
Crossref
Crossref
Steve Seung-Young Lee, Vytautas P. Bindokas & Stephen J. Kron. (2017) Multiplex three-dimensional optical mapping of tumor immune microenvironment. Scientific Reports 7:1.
Crossref
Crossref
Xiaohui Zhang, Yuanyuan Zeng, Qiuxia Qu, Jianjie Zhu, Zeyi Liu, Weiwei Ning, Hui Zeng, Nan Zhang, Wenwen Du, Cheng Chen & Jian-an Huang. (2017) PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. International Journal of Clinical Oncology 22:6, pages 1026-1033.
Crossref
Crossref
Federica SalettaRicardo E. VilainAditya Kumar GuptaSumanth NagabushanAysen YukselDaniel CatchpooleRichard A. ScolyerJennifer A. ByrneGeoffrey McCowage. (2017) Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma. JCO Precision Oncology:1, pages 1-12.
Crossref
Crossref
Nyanbol Kuol, Lily Stojanovska, Kulmira Nurgali & Vasso Apostolopoulos. (2017) The mechanisms tumor cells utilize to evade the host's immune system. Maturitas 105, pages 8-15.
Crossref
Crossref
Balázs Ács, Lilla Madaras, Anna-Mária Tőkés, Attila Kristóf Kovács, Erzsébet Kovács, Magdolna Ozsvári-Vidákovich, Ádám Karászi, Ede Birtalan, Magdolna Dank, Attila Marcell Szász & Janina Kulka. (2017) PD-1, PD-L1 and CTLA-4 in pregnancy-related – and in early-onset breast cancer: A comparative study. The Breast 35, pages 69-77.
Crossref
Crossref
Hyein Ahn, Jeong Mi Yang, Hyojin Kim, Jin-Haeng Chung, Soon-Hyun Ahn, Woo-Jin Jeong & Jin Ho Paik. (2017) Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma. Oncotarget 8:39, pages 66178-66194.
Crossref
Crossref
Elisabetta Cavalcanti, Raffaele Armentano, Anna Maria Valentini, Marcello Chieppa & Maria Lucia Caruso. (2017) Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death & Disease 8:8, pages e3004-e3004.
Crossref
Crossref
Junli Xue, Chunhua Chen, Manlong Qi, Yan Huang, Lin Wang, Yong Gao, Haidong Dong & Kun Ling. (2017) Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB. Oncotarget 8:26, pages 42414-42427.
Crossref
Crossref
Hitomi Mori, Makoto Kubo, Rin Yamaguchi, Reiki Nishimura, Tomofumi Osako, Nobuyuki Arima, Yasuhiro Okumura, Masayuki Okido, Mai Yamada, Masaya Kai, Junji Kishimoto, Yoshinao Oda & Masafumi Nakamura. (2017) The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget 8:9, pages 15584-15592.
Crossref
Crossref
Julia Y. S. Tsang, Wai-Ling Au, Kwan-Yin Lo, Yun-Bi Ni, Thazin Hlaing, Jintao Hu, Siu-Ki Chan, Kui-Fat Chan, Sai-Yin Cheung & Gary M. Tse. (2017) PD-L1 expression and tumor infiltrating PD-1+?lymphocytes associated with outcome in HER2+?breast cancer patients. Breast Cancer Research and Treatment 162:1, pages 19-30.
Crossref
Crossref
Sol?ne-Florence Kammerer-Jacquet, Laurence Crouzet, Ang?lique Brunot, Julien Dagher, Ad?la?de Pladys, Julien Edeline, Brigitte Laguerre, Benoit Peyronnet, Romain Mathieu, Gr?gory Verhoest, Jean-Jacques Patard, Alexandra Lespagnol, Jean Mosser, Marc Denis, Yosra Messai, Sophie Gad-Lapiteau, Salem Chouaib, Marc-Antoine Belaud-Rotureau, Karim Bensalah & Nathalie Rioux-Leclercq. (2017)
Independent association of PD-L1 expression with noninactivated
VHL
clear cell renal cell carcinoma-A finding with therapeutic potential
. International Journal of Cancer 140:1, pages 142-148.
Crossref
Crossref
Anja Derer, Martina Spiljar, Monika Bäumler, Markus Hecht, Rainer Fietkau, Benjamin Frey & Udo S. Gaipl. (2016) Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells. Frontiers in Immunology 7.
Crossref
Crossref
Lian Zhao, Haibo Yu, Shuijing Yi, Xiaowei Peng, Peng Su, Zhiming Xiao, Rui Liu, Anliu Tang, Xiayu Li, Fen Liu & Shourong Shen. (2016) The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget 7:29, pages 45370-45384.
Crossref
Crossref
Scott B. LovitchScott J. Rodig. (2016) The Role of Surgical Pathology in Guiding Cancer Immunotherapy. Annual Review of Pathology: Mechanisms of Disease 11:1, pages 313-341.
Crossref
Crossref
Murugan Kalimutho, Kate Parsons, Deepak Mittal, J. Alejandro López, Sriganesh Srihari & Kum Kum Khanna. (2015) Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends in Pharmacological Sciences 36:12, pages 822-846.
Crossref
Crossref
Tao Qin, Yin-duo Zeng, Ge Qin, Fei Xu, Jia-bin Lu, Wen-feng Fang, Cong Xue, Jian-hua Zhan, Xin-ke Zhang, Qiu-fan Zheng, Rou-jun Peng, Zhong-yu Yuan, Li Zhang & Shu-sen Wang. (2015) High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget 6:32, pages 33972-33981.
Crossref
Crossref
Yu Jin Lim, Jaemoon Koh, Kyubo Kim, Eui Kyu Chie, BoKyong Kim, Kyoung Bun Lee, Jin-Young Jang, Sun-Whe Kim, Do-Youn Oh, Yung-Jue Bang & Sung W. Ha. (2015) High ratio of programmed cell death protein 1 (PD-1)+/CD8+ tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. Radiotherapy and Oncology 117:1, pages 165-170.
Crossref
Crossref
S J Coles, M N Gilmour, R Reid, S Knapper, A K Burnett, S Man, A Tonks & R L Darley. (2015) The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29:9, pages 1952-1954.
Crossref
Crossref
Daniel E Carvajal-Hausdorf, Kurt A Schalper, Veronique M Neumeister & David L Rimm. (2015) Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. Laboratory Investigation 95:4, pages 385-396.
Crossref
Crossref
Daniel Sanghoon Shin & Antoni Ribas. (2015) The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Current Opinion in Immunology 33, pages 23-35.
Crossref
Crossref
Patcharee Ritprajak & Miyuki Azuma. (2015) Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncology 51:3, pages 221-228.
Crossref
Crossref
Sathana Dushyanthen, Peter Savas, Karen Willard-Gallo, Carsten Denkert, Roberto Salgado & Sherene Loi. (2015) Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?. Current Breast Cancer Reports 7:1, pages 59-70.
Crossref
Crossref
Lorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, Aitziber Buqué, Laura Senovilla, Elisa Elena Baracco, Norma Bloy, Francesca Castoldi, Jean-Pierre Abastado, Patrizia Agostinis, Ron N. Apte, Fernando Aranda, Maha Ayyoub, Philipp Beckhove, Jean-Yves Blay, Laura Bracci, Anne Caignard, Chiara Castelli, Federica Cavallo, Estaban Celis, Vincenzo Cerundolo, Aled Clayton, Mario P. Colombo, Lisa Coussens, Madhav V. Dhodapkar, Alexander M. Eggermont, Douglas T. Fearon, Wolf H. Fridman, Jitka Fučíková, Dmitry I. Gabrilovich, Jérôme Galon, Abhishek Garg, François Ghiringhelli, Giuseppe Giaccone, Eli Gilboa, Sacha Gnjatic, Axel Hoos, Anne Hosmalin, Dirk Jäger, Pawel Kalinski, Klas Kärre, Oliver Kepp, Rolf Kiessling, John M. Kirkwood, Eva Klein, Alexander Knuth, Claire E. Lewis, Roland Liblau, Michael T. Lotze, Enrico Lugli, Jean-Pierre Mach, Fabrizio Mattei, Domenico Mavilio, Ignacio Melero, Cornelis J. Melief, Elizabeth A. Mittendorf, Lorenzo Moretta, Adekunke Odunsi, Hideho Okada, Anna Karolina Palucka, Marcus E. Peter, Kenneth J. Pienta, Angel Porgador, George C. Prendergast, Gabriel A. Rabinovich, Nicholas P. Restifo, Naiyer Rizvi, Catherine Sautès-Fridman, Hans Schreiber, Barbara Seliger, Hiroshi Shiku, Bruno Silva-Santos, Mark J. Smyth, Daniel E. Speiser, Radek Spisek, Pramod K. Srivastava, James E. Talmadge, Eric Tartour, Sjoerd H. Van Der Burg, Benoît J. Van Den Eynde, Richard Vile, Hermann Wagner, Jeffrey S. Weber, Theresa L. Whiteside, Jedd D. Wolchok, Laurence Zitvogel, Weiping Zou & Guido Kroemer. (2014) Classification of current anticancer immunotherapies. Oncotarget 5:24, pages 12472-12508.
Crossref
Crossref